UK Government to fund four studies investigating long COVID
The UK Government will give £18.5 million in funding to four studies researching the causes and potential treatments of long COVID.
List view / Grid view
The UK Government will give £18.5 million in funding to four studies researching the causes and potential treatments of long COVID.
Researchers have shown that adding a polymer to glutamate-oxaloacetate transaminase means the molecule can treat stroke for up to six days in rats.
A proton therapy that targets cancer cells which are resistant to treatment has shown success, sparing surrounding healthy cells.
Researchers have synthesised peptides that function like a soluble chemokine receptor, blocking atherosclerosis in animal models.
Discover the latest in SARS-CoV-2 antibody research as we cover three of the most recent developments in this article.
Researchers studying SARS-CoV-2 at the individual cellular level have made four major discoveries about early infection from the coronavirus.
A study has shown that the ES17 phage binds to heparan sulphate and can target and eliminate ExPEC bacteria in animal models.
Jim Shanahan from SynDevRx explains why metabo-oncology treatment modalities could be the answer to a rise in metabolic disorders and cancers.
In a new study, inhibitors of the GLS1 enzyme caused the death of senescent cells and relieved the symptoms of various age-related diseases in mice.
According to scientists, maternal cells act as a reservoir for Zika, enabling the virus to pass from mother to foetus during pregnancy.
Researchers have discovered that thapsigargin has novel antiviral properties and is effective against COVID-19 in pre-clinical studies.
Analysis reveals people taking nucleoside reverse transcriptase inhibitors are significantly less likely to develop dry macular degeneration, a leading cause of age-related vision loss.
A new phenotype-based compound screening technology, called DeepCE, identified 10 compounds that could be repurposed for COVID-19.
Disrupting the interaction between the MYC oncogene and its co-factor, host cell factor (HCF)–1, was sufficient to cause Burkitt’s lymphoma cells to self-destruct in vivo.
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.